Time for digital marketing of migraine drugs has arrived in Japan

8 July 2021

As across the world, the migraine therapeutics landscape in Japan is growing with the recent approval of calcitonin gene-related peptide (CGRP) inhibitors as preventative treatment.

In this developing market, digital activity has not been prominent until now. However, it is expected to evolve with the recent approval of Amgen (Nasdaq: AMGN) and Teva’s (NYSE: TEVA) CGRP drugs, according to GlobalData.

"Amgen and Teva have been highly active across digital channels of various countries to promote themselves"The data and analytics company’s Pharmaceutical Intelligence Center estimates that the market size of migraine in Japan will grow at a compound annual growth rate (CAGR) of 8% from $165 million in 2021, to $365 million in 2029.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK